Edition:
United Kingdom

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

316.80DKK
3:59pm GMT
Change (% chg)

kr.3.00 (+0.96%)
Prev Close
kr.313.80
Open
kr.314.50
Day's High
kr.318.00
Day's Low
kr.312.90
Volume
317,364
Avg. Vol
438,075
52-wk High
kr.413.20
52-wk Low
kr.284.50

Select another date:

Fri, Jan 5 2018

BRIEF-H Lundbeck Enters Research Partnership On Treatment Of Schizophrenia

* LUNDBECK ENTERS RESEARCH PARTNERSHIP ON NOVEL TREATMENT OF SCHIZOPHRENIA

BRIEF-Lundbeck: Brintellix Approved In China

* LAUNCH IS EXPECTED TO COMMENCE IN Q2 2018. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Acorda announces royalty monetization transactions for $53 mln

* Acorda announces royalty monetization transactions for $53 million

Shares in Denmark's Lundbeck drop as sales of key drugs disappoint

COPENHAGEN, Nov 8 Shares in Danish pharmaceutical firm Lundbeck fell as much as 6.8 percent on Tuesday as third-quarter sales of its newer drugs, such as those to treat bipolar disorder and depression, undershot market expectations.

BRIEF-Lundbeck CEO sees U.S. prices to increase steadily

* INTERIM CEO SAYS EXPECTS U.S. PRICE INCREASES TO CONTINUE AT CURRENT LEVELS GOING FORWARD Further company coverage: (Reporting by Julie Astrid Thomsen)

BRIEF-Lundbeck Q3 EBIT above expectations at DKK 1.42‍​ bln

* LUNDBECK INCREASED OPERATING PROFIT (EBIT) WITH 126% AND EPS BY 182% IN THE FIRST NINE MONTHS OF 2017

BRIEF-Otsuka Canada Pharmaceutical says Health Canada approves Otsuka and Lundbeck's Abilify Maintena as treatment for bipolar I disorder in adults​

* Otsuka Canada Pharmaceutical Inc-Health Canada approves Otsuka and Lundbeck's Abilify Maintena as treatment for bipolar I disorder in adults​ Source text for Eikon: Further company coverage:

BRIEF-Otsuka Holdings unit and Lundbeck to initiate third Phase 3 trial to evaluate brexpiprazole in treatment of agitation in patients with dementia of Alzheimer's type

* Says co's unit Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S will initiate a third clinical phase 3 study for brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type, in the first half of 2018

BRIEF-Lundbeck and Otsuka will start third clinical phase III study

* ‍H. LUNDBECK A/S AND OTSUKA ANNOUNCE WILL INITIATE A THIRD CLINICAL PHASE III STUDY FOR BREXPIPRAZOLE​

BRIEF-Lundbeck says Anders Gotzsche to be interim CEO from Nov 1

* ‍BOARD DECIDED THAT AS OF NOV 1 ANDERS GÖTZSCHE WILL TAKE OVER OPERATIONAL MANAGEMENT OF CO AS INTERIM CEO UNTIL NEW CEO IS IN PLACE​ Source text for Eikon: Further company coverage:

Select another date: